Drug Trial Radar · NCT07684898
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Mar 9, 2027
Study completion Jun 21, 2027
Sponsor
- Lead sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The indication for this product is to control and prophylaxis in patients with Hemophilia A (congenital Factor VIII deficiency): The Primary Objective: To evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated patients with severe Hemophilia A. Secondary Objectives: To evaluate the health-related quality of life, pharmacokinetic (PK) profiles, safety and immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) for prophylactic treatment in previously treated subjects with severe Hemophilia A.
Conditions
- Severe Hemophilia A
Interventions
FRSW107Drug
For subjects in the PK subgroup: they will receive a dose of 50 IU/kg at the first dose visit 1 to obtain preliminary pharmacokinetic (PK) data. After assessment by the investigator, individualized prophylactic treatment (25\~50 IU/kg, Q3D) will be administered to maintain the trough concentration of FVIII activity at ≥1%. For subjects not in the PK subgroup: they will receive prophylactic treatment at a dose of 25\~50 IU/kg once every three days. If a subject experiences a breakthrough bleeding episode requiring treatment, the investigator shall determine the appropriate dosage (recommended dose range: 20\~50 IU/kg) and administration frequency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ABRTime frame: 6 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Fuyang Hospital, Affiliated to Anhui Medical University
Fuyang, China
Fujian Medical University Union Hospital
Fuzhou, China
Nanfang Hospital of Southern Medical University
Guangzhou, China
Anhui Provincial Hospital
Hefei, China
Jinan central hospital
Jinan, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
Affiliated Hospital of Nantong University
Nantong, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, China
Qinghai Provincial People's Hospital
Qinghai, China
The Second Hospital of Shanxi Medical University
Taiyuan, China
North China University of Science and Technology Affiliated Hospital
Tangshan, China
Wenzhou People's Hospital
Wenzhou, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
Wuhan, China
Affiliated Hospital of Jiangnan University
Wuxi, China
Xi'an Central Hospital
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China
Zhengzhou People's Hospital
Zhengzhou, China
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.